The pharmacological profile of mitragynine, particularly its partial agonism at mu-opioid receptors and interactions with serotonin and dopamine receptors, suggests an analgesic effect with potentially fewer side effects—such as reduced risk of respiratory depression and dependence—compared to conventional opioids. Here, OPRM1 is linked to respiratory depression.